A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

• Status: Completed
• Trial end date: 2020-08-24
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety of TRS01 eye drops in participants with active non-infectious anterior uveitis

.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tarsier Pharma; Tarsius Pharma
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• 18 years of age or older

• Able to provide informed consent, follow instructions and complete all required study visits for the duration of the study.

• Diagnosed with active non-infectious anterior uveitis requiring an increase or initiation of topical steroids for management of ocular inflammation.

An eligible subject must have:

• Non-infectious active anterior uveitis with anterior chamber cells Grade 2 or Grade 3, as specified per protocol.

• Must have vision ≥ 20/40 in the non-study eye.

• Use adequate birth control by men and women, if of reproductive potential and sexually active, as specified per protocol.

Exclusion Criteria:

• Any form of infectious uveitis

• Active retinitis

• Cancer or melanoma that is actively treated with immunotherapy

• Pregnancy / lactation

• Receiving specific medication/interventions as specified per protocol